Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-Risk Myelodysplastic Syndromes”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)WithdrawnNCT04361058
What this trial is testing

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

Who this might be right for
Leukemia, Myeloid, AcuteMyelodysplastic SyndromesMyelodysplastic Syndrome Acute Myeloid Leukemia
SCRI Development Innovations, LLC
Testing effectiveness (Phase 2)Looking for participantsNCT06471946
What this trial is testing

VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS

Who this might be right for
Higher-risk Myelodysplastic Syndromes
Navy General Hospital, Beijing 54
Early research (Phase 1)Looking for participantsNCT03113643
What this trial is testing

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm
Dana-Farber Cancer Institute 72
Testing effectiveness (Phase 2)Study completedNCT01546038
What this trial is testing

Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia
Pfizer 255
Early research (Phase 1)Ended earlyNCT04417517
What this trial is testing

Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

Who this might be right for
Higher Risk Myelodysplastic Syndromes
ALX Oncology Inc. 65
Testing effectiveness (Phase 2)Looking for participantsNCT06577441
What this trial is testing

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

Who this might be right for
Myelodysplastic Syndrome
National Cancer Institute (NCI) 54
Testing effectiveness (Phase 2)Study completedNCT01088373
What this trial is testing

Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 50
Testing effectiveness (Phase 2)Study completedNCT01593670
What this trial is testing

Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndrome
Masonic Cancer Center, University of Minnesota 9
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06598969
What this trial is testing

TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Who this might be right for
Myelodysplastic SyndromesMyeloid Leukemia, Acute
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 58
Testing effectiveness (Phase 2)Ended earlyNCT01204788
What this trial is testing

Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 5
Early research (Phase 1)Study completedNCT02920541
What this trial is testing

Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukaemia (AML)Myelodysplastic Syndrome (MDS)
Institut de Recherches Internationales Servier 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT05038592
What this trial is testing

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

Who this might be right for
Chronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia-1Chronic Myelomonocytic Leukemia-2+1 more
M.D. Anderson Cancer Center 64
Not applicableAvailableNCT01881334
What this trial is testing

Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants

Who this might be right for
Hematologic MalignanciesInborn Errors of Metabolism DisordersImmune Deficiencies
Joanne Kurtzberg, MD
Testing effectiveness (Phase 2)Active Not RecruitingNCT03674411
What this trial is testing

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphocytic LeukemiaBiphenotypic/Undifferentiated Leukemia+8 more
Masonic Cancer Center, University of Minnesota 22
Early research (Phase 1)Study completedNCT00101296
What this trial is testing

Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Erythroid Leukemia (M6)Adult Acute Megakaryoblastic Leukemia (M7)+16 more
National Cancer Institute (NCI) 30
Early research (Phase 1)Study completedNCT02078609
What this trial is testing

A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
AML and High Risk MDS
Novartis Pharmaceuticals 70
Testing effectiveness (Phase 2)Looking for participantsNCT03589729
What this trial is testing

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Who this might be right for
Acute Myeloid LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlasts 10 Percent or More of Bone Marrow Nucleated Cells+4 more
M.D. Anderson Cancer Center 100
Testing effectiveness (Phase 2)Study completedNCT02728050
What this trial is testing

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Biphenotypic LeukemiaAcute Myeloid Leukemiade Novo Myelodysplastic Syndrome+2 more
University of Washington 84
Testing effectiveness (Phase 2)Study completedNCT04487106
What this trial is testing

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Who this might be right for
Recurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center 21
Testing effectiveness (Phase 2)Study completedNCT01839916
What this trial is testing

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)+61 more
University of Chicago 77
Next Page